Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China.
J Cell Biochem. 2019 Jun;120(6):9724-9736. doi: 10.1002/jcb.28253. Epub 2018 Dec 23.
Adamantinomatous craniopharyngiomas (adaCP) accounts for 5.6% to 15% of intracranial tumors. High expression of chemokine (C-X-C motif) ligand 12 (CXCL12, also known as stromal cell-derived factor 1 [SDF1]) and its receptor CXC receptor type 4 (CXCR4) are widespread in various malignancy via multiple signal transduction pathways. This study aims to investigate the mechanism of CXCL12/CXCR4 promoting proliferation, migration, and invasion of adaCP.
Quantitative real-time polymerase chain reaction, Western blot analysis, and immunohistochemistry were used to evaluate the expression of CXCL12/CXCR4 mRNA and protein in 10 human adaCP tissues. Three successfully primary cell lines were obtained from native mainly solid tumor specimens, and confirmed by the means of inverted contrast microscope directly and following hematoxylin and eosin staining. Immunofluorescence was used to detect protein expression in vivo for the verification of primary cell line. Proliferation, migration, and invasion assays were performed to assess the biological functional role of CXCL12/CXCR4 in adaCP. The signal pathways involved in the action of CXCL12/CXCR4 in adaCP were also evaluated.
CXCL12 and CXCR4 were highly expressed in human adaCP samples. Primary adaCP cells were isolated and detected by the means of immunofluorescence for the detection of pan cytokeratin (pan-CK) and vimentin (VIM). Overexpression of CXCL12/CXCR4 significantly promoted the proliferation, migration, and invasion of primary adaCP cells. Moreover, cancer-promoting activity of CXCL12/CXCR4 is partially through its facilitation of PI3K/AKT signal pathway.
Our data showed that CXCL12/CXCR4 promotes adaCP proliferation, migration, and invasion through PI3K/AKT signal pathway. These findings suggested that therapeutic strategies regulating CXCL12/CXCR4 expression may provide an effective treatment of adaCP.
造釉细胞瘤占颅内肿瘤的 5.6%至 15%。趋化因子(C-X-C 基序)配体 12(CXCL12,也称为基质细胞衍生因子 1[SDF1])及其受体 CXC 受体 4(CXCR4)在多种恶性肿瘤中通过多种信号转导通路广泛表达。本研究旨在探讨 CXCL12/CXCR4 促进造釉细胞瘤增殖、迁移和侵袭的机制。
采用实时定量聚合酶链反应、Western blot 分析和免疫组织化学方法检测 10 例人造釉细胞瘤组织中 CXCL12/CXCR4mRNA 和蛋白的表达。从天然主要实体肿瘤标本中获得三个成功的原代细胞系,并通过倒置相差显微镜直接观察和苏木精-伊红染色后进行鉴定。免疫荧光法用于检测体内蛋白表达,以验证原代细胞系。增殖、迁移和侵袭实验评估 CXCL12/CXCR4 在造釉细胞瘤中的生物学功能作用。还评估了 CXCL12/CXCR4 在造釉细胞瘤中的作用涉及的信号通路。
CXCL12 和 CXCR4 在人造釉细胞瘤样本中高表达。通过免疫荧光法检测 pan 细胞角蛋白(pan-CK)和波形蛋白(VIM)检测原代造釉细胞瘤细胞的分离和检测。过表达 CXCL12/CXCR4 显著促进原代造釉细胞瘤细胞的增殖、迁移和侵袭。此外,CXCL12/CXCR4 的促癌活性部分通过其促进 PI3K/AKT 信号通路。
我们的数据表明,CXCL12/CXCR4 通过 PI3K/AKT 信号通路促进造釉细胞瘤的增殖、迁移和侵袭。这些发现表明,调节 CXCL12/CXCR4 表达的治疗策略可能为造釉细胞瘤提供有效的治疗方法。